Physician profile
Debra Witthar
NPI 1760090427
$11,157.71
in general payments reported to CMS, 2019-2025
21 companies · $3,009 in 2025
The $3,009 reported for 2025 was more than what 97% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $344 · 2022: $4,081 · 2023: $2,103 · 2024: $1,621 · 2025: $3,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,370 · Travel and Lodging: $1,630 · Food and Beverage: $1,564 · Honoraria: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,369.50 |
| Travel and Lodging | $1,630.07 |
| Food and Beverage | $1,563.90 |
| Honoraria | $1,170.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,165.91 | 2022-2025 | Infinity |
| Mdd US Operations, LLC | $1,865.75 | 2023-2025 | Gocovri, Gocovri |
| Boston Scientific Corporation | $1,173.98 | 2022-2023 | |
| Tanabe Pharma America, INC. | $1,027.13 | 2025 | |
| Acadia Pharmaceuticals INC | $983.79 | 2021-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $712.87 | 2021-2023 | Rytary |
| Abbvie INC. | $363.57 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $325.39 | 2021-2023 | Ongentys, Ingrezza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $148.65 | 2024 | Lifevest |
| Teva Pharmaceuticals USA, INC. | $82.17 | 2022-2023 | Austedo |
| Cala Health, INC. | $46.01 | 2022-2023 | Cala Trio |
| Merz Pharmaceuticals, LLC | $45.77 | 2023 | Xeomin |
| Sunovion Pharmaceuticals INC. | $38.97 | 2021-2022 | |
| Ucb, INC. | $38.65 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $27.46 | 2023 | Dysport |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $21.42 | 2024 | Cleviprex |
| Avion Pharmaceuticals | $21.19 | 2023 | Dhivy |
| Acorda Therapeutics, INC | $19.63 | 2022 | |
| Allergan, INC. | $19.47 | 2021 | |
| Adamas Pharmaceuticals, INC. | $17.20 | 2021 | |
| Azurity Pharmaceuticals, INC. | $12.73 | 2023 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Witthar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.